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Background: Routine clinical application of circulating tumour cells (CTCs) for blood based diagnostics is yet to 
be established. Despite growing evidence of their clinical utility for diagnosis, prognosis and treatment monitoring, 
the efficacy of a robust platform and universally accepted diagnostic criteria remain uncertain. We evaluate the 
diagnostic performance of a microfluidic CTC isolation platform using cytomorphologic criteria in patients 
undergoing lung cancer surgery. 
Methods: Blood was processed from 51 patients undergoing surgery for known or suspected lung cancer using 
the ClearBridge ClearCell FX systemTM (ClearBridge Biomedics, Singapore). Captured cells were stained on slides 
with haematoxylin and eosin (H&E) and independently assessed by two pathologist teams. Diagnostic performance 
was evaluated against the pathologists reported diagnosis of cancer from surgically obtained specimens. 
Results: Cancer was diagnosed in 43.1% and 54.9% of all cases. In early stage primary lung cancer, between 
the two reporting teams, a positive diagnosis of CTCs was made for 50% and 66.7% of patients. The agreement 
between the reporting teams was 80.4%, corresponding to a kappa-statistic of 0.61±0.11 (P<0.001), indicating 
substantial agreement. Sensitivity levels for the two teams were calculated as 59% (95% CI, 41–76%) and 41% (95% 
CI, 24–59%), with a specificity of 53% for both. 
Conclusions: The performance of the tested microfluidic antibody independent device to capture CTCs using 
standard cytomorphological criteria provides the potential of a diagnostic blood test for lung cancer. 
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Introduction
Identification of circulating tumour cells (CTC) in 
the blood of patients with cancer is now established in 
numerous cancers (1-3). The principals of cell capture is 
either using positive (e.g., cell size, antigen expression) (4-7) 
or negative (e.g., depletion of normal cells) selection (8) 
each having benefits and limitations. To date, the use of 
CTCs in routine clinical management has been limited to 
the current epithelial cell adhesion molecule (EpCAM)-
based immunomagnetic approaches that only detect CTCs 
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that express EpCAM, such as the CellSearch device (3). 
FDA approval for the CellSearch currently exists only 
for metastatic breast, prostate and colorectal cancer, 
thus excluding those CTCs with absent or low EpCAM 
expression as is the case with lung. Numerous reports have 
found low CTC recovery in non-epithelial and metastatic 
cancers such as melanoma, ovarian, pancreatic, and lung 
(9,10), underscoring the need for improved, unbiased CTC 
recovery technologies.
Once cells are captured, the next step is to characterise 
and correctly identify cancer cells, which has proved 
challenging in the context of generally low CTC loads 
(particularly in early cancer). There is also a lack of 
consensus of the diagnostic criteria used, and some of the 
criteria applied are not widely accepted e.g., E-cadherin or 
vimentin expression (11). Pathological criteria for diagnosis 
should be achieved amongst pathologists and professionals 
alike. 
Recently the ClearBridge ClearCell FX systemTM 
(ClearBridge Biomedics, Singapore) was developed 
consisting of a spiral microfluidic device, separating 
and enriching CTCs from whole blood, based on cell 
size. Smaller haematological cells (red blood cells and 
leucocytes), 8–15 µm are affected by the Dean drag 
force and migrate to the outer wall, where larger CTCs 
(15–20 µm) are subjected to stronger inertial lift forces and 
focussed along the microchannel inner wall (12), resulting 
in a concentrated cell suspension.
This study evaluates the performance of the ClearBridge 
ClearCell FX systemTM to identify circulating lung cancer 
cells using conventional cytomorphological criteria assessed 
through haematoxylin and eosin (H&E) staining, and light 
microscopy, and define the test performance against an 
underlying diagnosis of cancer in patients with known or 
suspected lung cancer. 
Methods
The study was carried out at the Royal Brompton & 
Harefield NHS Foundation Trust. The project was 
approved under the auspices of the National Institute 
of Health Biomedical Research Unit Advanced Disease 
Biobank (NRES 10/H0504/10). 
A total of 52 participants were enrolled on the study, 
36 of whom were patients with known or suspected lung 
cancer undergoing lung surgery, the remaining 16 consisted 
of healthy volunteers and non-cancer patients. All patients 
donated 7.5 mL of blood, one sample was excluded due 
to artefacts of blood processing, in total the final cohort 
consisted of 51 patients. The baseline characteristics of the 
patient are summarised in Table 1. 
Peripheral blood was collected in 9 mL EDTA 
vacutainers or Streck tubes, either prior to surgery for 
surgical patients, and in clinics for all others, samples were 
processed within 24 hours for EDTA samples, and within 
72 h for Streck tubes. The ClearBridge ClearCell FX 
systemTM (ClearBridge Biomedics) was used to capture and 
enrich CTCs according to the manufacturers protocol. 
Briefly, 7.5 mL of blood was mixed with 22.5 or 30 mL of 
red blood cell lysis buffer (G-Biosciences, St. Louis, MO, 
USA) at room temperature for 10 min. After incubation 
the samples were centrifuged at 500 g for 10 min followed 
by aspiration of supernatant, and finally addition of 4.3 mL 
of suspension reagent supplied by the manufacturer. The 
samples were then processed through the ClearCellTM 
system using a CTC ChipTM FR1 and microfluidics 
technology to separate tumour cells from white blood cells, 
to form an enriched suspension of CTCs. Processed samples 
were air dried on to glass slides and subjected to standard 
H&E staining, and then reported independently by two 
histopathologists. Results were categorised into “negative” 
or “positive” for cells suggestive of tumour, based on the 
Table 1 Baseline characteristics
Variable Value Percent (%)
Total 51 100
Age, mean ± SD (years) 57.0±15.1 –
Males/females 27/24 52.9/47.1
Pathology
Primary lung cancer 24 47.1
Adenocarcinoma 17 70.8
Squamous cell carcinoma 6 25.0
Small cell carcinoma 1 4.2
Metastatic cancer 8 15.7
Non-cancer control 19* 37.3
Staging#
I–II 18 90.0
III–IV 2 10.0
*, lymphoma, hamartoma, fibrosis, eleven cases of sarcoid, and 
five healthy volunteers; #, staging data not available for four  
patients.
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presence of nucleated cells with high nuclear/cytoplasmic 
ratios that were larger than resting lymphocytes and/or cells 
having irregular nuclear outlines. 
Inter-pathologist agreement was measured by Cohen’s 
kappa statistic and diagnostic utility was calculated as 
sensitivity, specificity, positive and negative predictive values 
and expressed with a 95% confidence interval. Statistical 
analyses were performed on Stata 13 (College Station, 
Texas, USA).
Results
From 30 July to 15 December 2015, blood specimens were 
processed from 51 participants with a mean age (SD) of 57 
(15.04), 53% were male and primary lung cancer diagnosed 
in 24 (47%), secondary cancer diagnosed in 8 (16%) and 
no cancer (healthy control) in 19 (37%). Atypical cells 
suggestive of cancer were detected in an average of 49% of 
all cases, and 78.4% in all cancer cases. In early stage cancer 
this ranged from 50% and 66.7%, and late stage 0% and 
100.0% for the first and second reporting team respectively. 
In both reporting groups, 9 (47.3%) of cases were reported 
as being suspicious of atypical cancer cells, despite being 
part of the benign cohort. 
Based on the capture of CTCs and H&E staining (Figure 1), 
the diagnosis of cancer was reported for 28 (88%) and 22 
(69%) of patients of the cancer group by each pathologist 
team respectively. The between pathologist agreement was 
80% with a kappa (SE) of 0.61 (0.11; P<0.001) indicating 
substantial agreement according to Landis and Koch 
criteria (13). 
Sensitivity, specificity, positive and negative predictive 
values  were est imated for  each pathologist  team 
independently and were poor, as reported in Table 2. 
Discussion
Various studies have shown the ability to isolate and capture 
CTCs in lung cancer patients, using a range of platforms, 
from antibody based (14,15) to filtration based techniques 
(4,5), with varying levels of performance and success. 
The purpose of this study was to assess the ability of the 
Figure 1 Images of H&E stained slides. H&E stained slides (×40) of captured atypical cells suspicious for cancer. (A-C) show slides positive 
cells (arrow), amongst much smaller contaminating leukocytes. (D) is a negative slide with only leukocytes present. H&E, haematoxylin and 
eosin.
A B
C D
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Table 2 Test performance statistics (95% CI) for the diagnosis of cancer using a spiral-chip microfluidic platform for capture of atypical cancer 
cells in the peripheral bloodstream
Reading First reporting team (%) Second reporting team (%)
Sensitivity 59 [41–76] 41 [24–59]
Specificity 53 [29–76] 53 [29–76]
Positive predictive value 68 [48–84] 59 [36–79]
Negative predictive value 44 [23–66] 34 [18–54]
ClearBridge ClearCell FX systemTM to isolate CTCs in the 
peripheral blood of surgical patients known or suspected of 
having lung cancer, using standard cytomorphologic criteria 
in a clinical setting. 
Our investigation builds on the knowledge from 
previous studies, including studies by our group using 
a microfluidic biochip by ClearBridgeTM (4),  and 
using another antibody independent filtration device, 
ScreenCellTM (5). Other similar studies for lung cancer 
include those using the device ISET, as well as the FDA 
approved antibody based platform, CellSearchTM (16). 
Although CellSearchTM results proved less efficient. 
Many groups took to comparing performances of 
differing devices, particularly in the context of antibody 
independent and antibody based, to enhance the argument 
of EpCAM loss and antibody bias, as is known to be the 
case in lung cancer (3,16,17).
We also report atypical cells with cytomorphological 
features suggestive of cancer identified within the ‘non 
cancer control’ group. Whilst these might represent true 
cancer cells in patients who may subsequently develop 
clinical features of cancer, they are more likely to be false 
positive results, with the cells representing other cell types, 
such as larger lymphoreticular cells. Further studies will be 
required using immunohistochemistry to help define this 
cell population more accurately and to refine the diagnosis 
of tumour cells when identified. 
Currently focus has shifted to the development of 
circulating free nucleic acids (ctNA) monitoring and 
measuring techniques as an alternative to CTCs. ctNAs 
are more abundant in comparison, accounts for tumour 
heterogeneity unlike individual  CTCs, and more 
importantly allows for real time mutation profiling and 
resistance development (18-20). It has been reported that 
several studies have shown correlations between mutations 
found in the tumour and blood in excess of 95% (21). Other 
studies evaluating their effectiveness have thus far reported 
positive results (20,22,23) suggesting a shift towards 
ctNAs as a more robust blood based biomarker, possibly in 
combination with CTCs.  
The results of this study are not substantive to support 
clinical application of this microfluidic CTC capture 
platform, for CTC detection using standard H&E staining 
for clinical diagnosis in its current form. Sensitivity and 
specificity are generally quite poor at 59% and 41%, and 
53% for both reporting teams, respectively, owing to either 
the analytic sensitivity of the method or the absence of 
CTCs in the samples, coupled with a poor recovery rate 
of approximately 40%. The results also indicate a level of 
subjectivity amongst the pathologists which is reflected in 
the inter observer agreement of 80.4%. Despite a significant 
kappa statistic of 0.61 (P<0.001) between the reporting 
groups, there is clearly some ambiguity and subjectivity 
in the diagnostic criteria, particularly in the context of 
standard H&E staining and, as discussed above, application 
of immunohistochemistry will need to developed in this low 
cellularity environment. 
The implementation of a robust CTC isolation platform 
for CTC quantification in to the clinical setting could have 
potentially multiple benefits as has been demonstrated, 
ranging from prognosis and diagnostics, to treatment 
monitoring (2,24,25). However, at current the test 
performance of the ClearBridge ClearCell FX systemTM 
device improvements are still required before clinical 
application, with further work to be undertaken with cell 
characterisation and more specific staining techniques to 
identify cancer.  
Conclusions
The findings of our study suggest that a spiral microfluidic 
antibody independent platform to capture CTCs using 
standard H&E staining and light microscopy assessment 
has the potentials as a diagnostic blood test for lung cancer, 
however implementation in a clinical setting requires 
further validation. 
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